Trials / Terminated
TerminatedNCT04201782
Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T
Long-Term Follow-up of HIV-Infected Subjects Treated With Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases (SB-728-T or SB-728mR-T)
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 38 (actual)
- Sponsor
- Sangamo Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Long-term follow-up of HIV-infected subjects who received SB-728-T or SB-728mR-T. Enrolling subjects will be followed for a total of 12 years.
Detailed description
Subjects infected with HIV who have received therapy with SB-728-T or SB-728mR-T will be eligible to participate in this trial. There will be no treatment in this long-term follow-up study. Subjects who choose to enroll into this extension study will be evaluated for a total of 12 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | There are no disallowed treatments | Genetic: SB-728-T or SB-728mR-T No study drug is administered in this study. Subjects who received SB-728-T or SB-728mR-T in a previous trial will be evaluated in this trial for long-term safety and efficacy. |
Timeline
- Start date
- 2011-03-18
- Primary completion
- 2023-07-17
- Completion
- 2023-07-17
- First posted
- 2019-12-17
- Last updated
- 2024-01-26
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04201782. Inclusion in this directory is not an endorsement.